Sensenig Bethany
- SEC CIK
- 0001899935
In the past year, 1 open-market sale filing worth $228.3K and no purchases.
Current role at each company
- KALV KalVista Pharmaceuticals, Inc.Directoras of Jun 11, 2026
- ACOG Alpha Cognition Inc.Directoras of Apr 17, 2026
- SUPN Supernus Pharmaceuticals, Inc.Directoras of Feb 23, 2026
- NMTR 9 Meters Biopharma, Inc.Chief Financial Officeras of Apr 21, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $228.3K
- 1 filing
- Net
- −$228.3K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Sensenig Bethany as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
SUPN Supernus Pharmaceuticals, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 (view filing) | Feb 19 | 4 days | Sensenig BethanyDirector | SSale | −4.47K | $51.01 | −$228.3K | −100.0%0 after | 2 lots10b5-1 |
| Aug 18, 2025 (view filing) | Aug 14 | 4 days | Sensenig BethanyDirector | SSale | −5.37K | $42.25 | −$226.8K | −100.0%0 after | 10b5-1 |
NMTR 9 Meters Biopharma, Inc.
Chief Financial Officer1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 21, 2023 (view filing) | Apr 21 | Same day | Sensenig BethanyChief Financial Officer | SSale | −9.10K | $1.21 | −$11.0K | −18.1%41.1K after |